Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8785501 Anti-cancer tamoxifen-melatonin hybrid ligand

Patent 8785501 was granted and assigned to Duquesne University on July, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Duquesne University

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

87855010

Patent Inventor Names

David Lapinsky0

Paula A. Witt-Enderby0

Vicki L. Davis0

Date of Patent

July 22, 2014

Patent Application Number

134979540

Date Filed

October 12, 2010

Patent Citations Received

‌

US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds

‌

US Patent 11834458 Anti-cancer nuclear hormone receptor-targeting compounds

‌

US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds

Patent Primary Examiner

‌

Layla Soroush

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8785501 Anti-cancer tamoxifen-melatonin hybrid ligand

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API